Drug Discovery@nature.com 20 July 2012

Advertisement JAX® In Vivo Pharmacology Services - Mouse Models of Lupus Leverage expertise and save time. We specialize in efficacy studies using recognized mouse models and readouts of human systemic lupus erythematosus. We have extensive experience with the most published mouse models of lupus, the MRL-lpr/lpr and NZBWF1 mice. Learn more. TABLE OF CONTENTS 20 July 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Scientific Reports publishes 457 open access papers in its first year Publishing technically sound research articles, Scientific Reports is Nature Publishing Group's fastest growing journal. Given the speed and visibility offered, no wonder 93% of our authors said that they are "likely" or "very likely" to submit again. Keep your research moving. Submit to Scientific Reports   News Top First FDA-approved beta-amyloid diagnostic hits the market doi:10.1038/nbt0712-575 Eli Lily’s beta-amyloid imaging agent for cases of suspected Alzheimer's disease is now commercially available. Full Text California's CIRM courts industry doi:10.1038/nbt0712-572 The California Institute for Regenerative Medicine will shift its emphasis from basic research to translation, working in partnership with industry. Full Text Gene mutation defends against Alzheimer's disease doi:10.1038/487153a A rare genetic variant suggests a cause and treatment for cognitive decline. Full Text Law spurs regulators to heed patients' priorities doi:10.1038/487154a US FDA to consider risks and benefits more explicitly in drug approvals. Full Text Analysis Top Blood brain barrier in a dish doi:10.1038/scibx.2012.694 Wisconsin researchers have used cultured human stem cells to engineer an artificial blood brain barrier. The technology could help companies identify drug candidates that readily enter the brain or that decrease BBB permeability. Full Text FDA advisory committee meeting outcomes doi:10.1038/nrd3747 This analysis of the outcomes of advisory committee meetings held by the US FDA over the past decade investigates issues such as the consistency between advisory committee votes and FDA approval decisions. Full Text Pipeline pioneers: Vismodegib doi:10.1038/nrd3753 First-in-class inhibitor of the Hedgehog signalling pathway approved in the United States for the treatment of basal cell carcinoma. Full Text Research Highlights Top Cancer: Of targets and anti-targets doi:10.1038/nrd3781 Polypharmacology is difficult to predict. Now, researchers have taken a systems pharmacology approach, identifying targets and anti-targets for the rational design of drugs with an optimized polypharmacological profile. Full Text Metabolic disorders: Heart microRNA provides new route to metabolic control doi:10.1038/nrd3779 Researchers have discovered a novel role of the heart in systemic metabolic control and suggest that miR-208a inhibition may have applications in the treatment of metabolic disorders. Full Text Anticancer drugs: Antipsychotic to anticancer agent? doi:10.1038/nrd3783 A new study has screened for compounds that selectively differentiate cancer stem cell-like cells and has identified dopamine receptor antagonists as promising candidates. Full Text Research & Reviews Top Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars doi:10.1038/nrd3746 This review looks at the analytical technologies available to assess biosimilars, focusing on the assessment of post-translational modifications, three-dimensional structures and protein aggregation. Full Text Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma doi:10.1038/nrd3745 This Review discusses the current state of ocular drug therapy and highlights future therapeutic opportunities. Full Text IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4CD8-entheseal resident T cells doi:10.1038/nm.2817 The identification of an IL-23-responsive CD4-CD8- T cell population points to new therapeutic targets for this group of rheumatic disorders. Full Text A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis doi:10.1038/nm.2826 Researchers have discovered a new axis that mediates the pathogenic progression of endometriosis, and suggest that the antibody to TNF-α etanercept might offer a therapy. Full Text Drug Discovery JOBS of the week Principal Investigator positions in Biological Chemistry & Drug Discovery University of Dundee, College of Life Sciences Postdoctoral Position in Drug Discovery Research Shanghai Jiao Tong University Shanghai Center for Systems Biomedicine Postdoctoral Fellow Sanford-Burnham Medical Research Institute Institute Research Scientist � Drug Metabolism MD Anderson Cancer Center PhD studentship on large-scale quantum chemistry methods applied to drug discovery University of Southampton - Chemistry More Science jobs from Drug Discovery EVENT Allosteric Regulation of Cell Signalling 17.-19.09.12 Madrid, Spain More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.